Owner Scorecard


← All companies ← ADC Manual ADEA → ← ADAG Pharmaceuticals AGIO →

ADCT, ADC Therapeutics SA

Pharmaceuticals consumer brand UnprofitableDistress / turnaround

ADC Therapeutics is a commercial-stage global pioneer in the field of antibody drug conjugates, transforming treatment for patients through our focused portfolio with ZYNLONTA, a CD19-directed ADC.

Food and Drug Administration ("FDA") and conditional approval from the European Commission, China National Medical Products Administration ("NMPA") and Health Canada for the treatment of relapsed or refractory DLBCL after two or more lines of systemic therapy.

The following table provides an overview of our current approved product and pipeline: In addition to the current approved product and pipeline above, IND-enabling activities for ADCT-241 (the Company's exatecan-based, prostate-specific membrane antigen (PSMA)-targeting ADC) were completed at the end of 2025.

Latest annual: FY2025 10-K
ADCT · ADC Therapeutics SA
I

The business

What it sells, where the money comes from, the kind of company it is.

Revenue · FY2025
$81M
+14.9% YoY · −27% 3-yr CAGR
Vital signs · TTM
Cash & investments $219M
Cash burn · annual $102M
Runway 2.1 yrs

Next report By 11/13 · the 10-Q for the quarter ended late September · due within 45 days of period end · has filed ~43 days after · the wire records it on arrival

The business in brief

read the 10-K →

What this business is and what moves its needle, from its own SEC filings.

Situation
Unprofitable. No sustained operating profit across the record; an earnings multiple has nothing to rest on. What the record does show is revenue, the gross-margin trajectory, and the burn against the cash on hand. Distress / turnaround. Thin interest coverage, or operating cash burned against real debt, across the record. The balance sheet carries this situation; the debt schedule sets the clock.
What moves the needle
Operating margin has run around −167% through the cycle on a 93% gross margin, the operating line in the red even at its best — so the lever is whether the spending below the gross line can come down enough to clear a profit: revenue growth against the cost curve, and the cash runway until it does. Stock-based pay runs about 9.3% of sales, a real and recurring claim on owners that the GAAP margin understates. Read this kind of business on the pipeline against the patent cliff, and pricing. On its own account, the filing leans hardest on pricing power & competition, set against the numbers in what the filing emphasizes, below.

Every line is arithmetic on the company's filings, shown in full in the sections below.

II

The record

Ten years of arithmetic, read across the cycle.

Most recent quarterly filing 10-Q filed Aug 13, 2026 Source at SEC EDGAR →

Revenue up 3.0% year over year

figures computed from the filing's XBRL

The record, 2022–2025

realized figures from each filing · older years to the left
2022’222023’232024’242025’25TTMTTMJun 2026
Income statement
$210M$70M$71M$81M$85MRevenueRevenue
$207M$65M$76M$79MGross profitGross prof.
98%92%93%93%Gross marginGross mgn
68%152%121%98%101%SG&A / revenueSG&A/rev
89%183%155%128%97%R&D / revenueR&D/rev
($123M)($166M)($131M)($121M)($100M)Operating incomeOp. inc.
−58.8%−238.6%−184.4%−149.3%−117.8%Operating marginOp. mgn
($147M)($195M)($156M)($142M)Pretax incomePretax
($157M)($240M)($158M)($143M)($97M)Net incomeNet inc.
Cash flow & returns
($138M)($119M)($124M)($141M)($102M)Operating cash flowOp. cash
$1M$1M$1M$705KDepreciationDeprec.
($32M)$107M$26M($6M)($15M)Working capital & otherWC & other
$687K$3M$867K$264K$32KCapexCapex
0.3%4.6%1.2%0.3%0.0%Capex / revenueCapex/rev
($139M)($122M)($125M)($141M)($102M)Owner earningsOwner earn.
−66.2%−175.3%−176.0%−173.8%−121.0%Owner earnings marginOE mgn
($139M)($122M)($125M)($141M)($102M)Free cash flowFCF
−66.2%−175.3%−176.0%−173.8%−121.0%Free cash flow marginFCF mgn
($687K)($3M)($867K)$395KInvesting cash flowInv. cash
($897K)$74M$97M$151MFinancing cash flowFin. cash
($208K)$184K($83K)$305KExchange-rate effectFX
($140M)($48M)($28M)$10MChange in cashΔ cash
Balance sheet
$326M$279M$251M$261M$219MCash & investmentsCash+inv
$12M$16M$2M$4M$5MInventoryInvent.
$12M$16M$18M$9M$13MAccounts payablePayables
($278K)$608K($16M)($5M)($8M)Operating working capitalOper. WC
$435M$336M$291M$306M$262MCurrent assetsCur. assets
$82M$68M$80M$70M$86MCurrent liabilitiesCur. liab.
5.3×5.0×3.6×4.4×3.0×Current ratioCurr. ratio
$3M$6M$5M$0Net PP&ENet PP&E
$491M$355M$322M$323M$279MTotal assetsAssets
$110M$113M$114M$116M$117MTotal debtDebt
($217M)($166M)($137M)($146M)($103M)Net debt / (cash)Net debt
-3.4×-3.6×-2.6×-2.4×-1.9×Interest coverageInt. cov.
$411M$503M$525M$509MTotal liabilitiesTotal liab.
$79M($148M)($203M)($186M)($228M)Shareholders’ equityEquity
23.5%19.4%9.3%8.5%11.4%Stock comp / revenueSBC/rev
Per share
78.2M81.7M97.2M127M155MShares out (diluted)Shares
$2.69$0.85$0.73$0.64$0.55Revenue / shareRev/sh
$-2.01$-2.94$-1.62$-1.12$-0.63EPS (diluted)EPS
$-1.78$-1.49$-1.28$-1.11$-0.66Owner earnings / shareOE/sh
$-1.78$-1.49$-1.28$-1.11$-0.66Free cash flow / shareFCF/sh
$0.01$0.04$0.01$0.00$0.00Cap. spending / shareCapex/sh
$1.02$-1.81$-2.09$-1.46$-1.48Book value / shareBVPS
Per-share growththe realized rate an owner's share compounded
3-yr5-yr
Revenue / share−38.0%/yr−38.0%/yr (3-yr)
Capital spending / share−38.2%/yr−38.2%/yr (3-yr)

Net income is the accountant's number; owner earnings is the cash an owner could take out. The walk between them, off the cash-flow statement, and whether the gap is widening or holding.

In fiscal 2025 the business turned a $143M loss into ($141M) of owner earnings: more cash than the profit line showed, after the non-cash charges and the capital it put back in.

FY2025FY2024FY2023FY2022
Reported net income($143M)($158M)($240M)($157M)
Depreciationnon-cash charge added back+$705K+$1M+$1M+$1M
Stock-based compensationreal costnon-cash, but a real cost+$7M+$7M+$13M+$49M
Working capital & othertiming of cash in and out, other non-cash items−$6M+$26M+$107M−$32M
Cash from operations($141M)($124M)($119M)($138M)
Capital expenditurecash put back in to keep running and to grow−$264K−$867K−$3M−$687K
Owner earnings($141M)($125M)($122M)($139M)
Owner-earnings marginowner earnings ÷ revenue-174%-176%-175%-66%

Owner earnings is the cash an owner could pull out without starving the business: operating cash less the capital it must spend to hold its position . The cash-flow statement also adds stock comp back as non-cash, but it is a real cost paid in shares; counted as the expense it is (less $7M), owner earnings is nearer ($148M).

Maintenance capex is estimated as depreciation where a growing business invests above it; free cash flow is the figure the scorecard's free-cash margin reads.

III

Quality & stewardship

Returns, the balance sheet, capital allocation, and pay.

Owner’s Scorecard

FY2025 10-K · source on SEC EDGAR →

Will it survive?

  • Does not cover its interest
    Operating income ($121M) ÷ interest expense $52M
    What this means

    A full year of operating profit didn't cover the interest bill. This is the zombie zone: the business depends on refinancing, asset sales, or forbearance to service its debt.

  • Net cash
    Cash $261M − debt $116M
    What this means

    Cash and short-term investments exceed every dollar of debt by $146M, on net the company owes nothing, and can act from strength when others can't. Net debt is the leverage figure that matters: the cash is already set against the debt. Strategic or illiquid investments aren't counted here.

  • Not enough data
    What this means

    The filing data didn't include the inputs for this check.

Is it a good business?

  • Not meaningful here
    Invested capital ($332M) = debt $116M + equity ($186M) − cash
    Industry peers: median -71%
    What this means

    Invested capital is near zero or negative, usually years of buybacks pulling equity down. ROIC explodes or flips sign and stops meaning anything. Judge this one on Owner Earnings instead.

  • Consumes cash through the cycle
    4-yr median margin, range -176%–-66%; latest ($141M) = operating cash ($141M) − maintenance capex $264K
    Industry peers: median -130%
    What this means

    What an owner could take out without starving the business: operating cash less the maintenance capital it must spend to hold its position — Buffett's owner earnings. That's -174% of revenue this year, a -175% median across 4 years. Treating stock comp as the real expense it is (less $7M of SBC) leaves ($148M).

  • Loss, and burning cash
    Net income ($143M) · cash from operations ($141M)
    What this means

    The company reported a net loss, so a conversion ratio isn't meaningful. What matters then is whether operations still threw off cash, here, they did not.

How is the cash used?

  • Not enough data
    What this means

    The filing data didn't include the inputs for this check.

  • Investing or harvesting? 0.37×
    Harvesting
    Capex $264K ÷ property depreciation $705K
    What this means

    Descriptive, not a grade. Above ~1× means investing faster than assets wear out (growth, or, sustained for years, today's earnings carrying less depreciation than tomorrow's will). Below means spending less than it's wearing out (efficiency, or a melting asset base). The ratio won't tell you which; the filings will.

The promise and the pay packet

  • Growth is being bought
    Selling and marketing $43M ÷ revenue $81M
    What this means

    Sales and marketing as a share of revenue, kept apart from administrative overhead because it answers a different question: how much a business must spend to win the next customer. A company whose product pulls customers in spends little here and keeps the difference; one that must buy its growth is running to stand still, and the spending has to keep rising for revenue to keep rising. Read it beside the growth rate, not alone.

  • Is the buyback buying ownership, or mopping up? 8.5%
    The count is rising
    Stock compensation $7M (fiscal 2025), 8.5% of revenue · no repurchases · diluted shares +62.6% since 2022
    What this means

    Stock handed to employees is a real cost paid in the owner's own currency: it is charged against profit, but the shares it creates are permanent. Many companies repurchase stock at the same time, which looks like a return of capital and often is not — if the count barely moves, the cash merely cancelled the pay packet and bought the owner nothing. The three states worth telling apart are a count genuinely shrinking, a count standing still despite large repurchases, and a count rising because the issuance was never offset at all.

Graham’s defensive tests · 2 of 3 met

Graham’s numerical criteria for the defensive investor (The Intelligent Investor, ch. 14), run on the filings. A floor of safety, not a buy signal; many fine modern businesses fail his strictest liquidity rules by design.

  • Adequate size Miss
    Revenue ≥ $2B · $81M
    What this means

    Big enough to weather a storm. Graham's 1972 floor was ~$100M of sales (≈ $700M today); we use a $2B revenue line as a conservative modern stand-in.

  • Strong liquidity Pass
    Current ratio ≥ 2× · 4.37×
    What this means

    Current assets at least twice current liabilities, near-term bills covered without touching the business. Strict by design: many cash-rich modern firms run leaner and miss it, holding their cushion in longer-dated securities.

  • Conservative debt Pass
    Debt ≤ working capital · $116M vs $236M WC
    What this means

    Graham's rule that borrowings not exceed net current assets. Capital-heavy and buyback-heavy firms routinely fail it, read it next to interest coverage, not alone.

  • Moderate price
    P/E ≤ 15 and P/E × P/B ≤ 22.5 · decided by the price
    What this means

    Graham's valuation gate, the wall he kept between a sound business and a sound investment. Three-year average earnings are $-1.41/share (latest year $-1.12), the averaged base the calculator's gate runs on, and book value is $-1.46/share. Enter a price in “What the price implies” just below for the P/E, P/B, and whether it clears. But this is the rule Buffett outgrew: there's no hard P/E law, and a wonderful business can deserve a far richer multiple if the thesis holds, treat it as the bargain-hunter's floor, not a verdict on the price.

Durability & moat, 2022–2025

Whether the record’s returns held, and what the capital reinvested earned.

  • Profitable years 0 of 4
    What this means

    Lost money in 4 year(s), look at what happened there before trusting the average.

  • Operating margin −149% → −167% (2-yr avg ends)

    In the filing’s words The filing attributes gains to higher prices, but the margin in the record has not followed — the claim outruns the result here.

    What this means

    The recent-years average (−167%) sits below the early years (−149%), but the latest year (−149%) is back near the early level: a cyclical trough dragging the window down, not a one-way slide. The through-cycle median is −184% — read it across the cycle, not on the dip.

  • Worst year 2023 · −238.6% op. margin
    What this means

    Operations went underwater in 2023, understand why before trusting the good years.

  • Share count +17.6%/yr
    What this means

    The share count is rising, dilution works against you on a per-share basis.

All figures as filed; the source filing is linked above.

Current Position

as of the latest quarter, Jun 30, 2026

Can the business pay what it owes this year, off the freshest balance sheet: the quality of the assets, the debt actually coming due, and what a low ratio means here.

Current assets$262M
  • Cash & short-term investments$219M
  • Inventory$5M
  • Other current assets$38M
Current liabilities$86M
  • Debt due within a year$6M
  • Accounts payable$13M
  • Other current liabilities$67M
Current ratio3.03×all current assets ÷ what's due · Graham looked for 2×
Quick ratio2.97×stricter: inventory excluded
Cash ratio2.54×strictest: cash alone against what's due
Working capital$175Mthe cushion left after near-term bills
Debt due this year vs. cash$6M due · $219M cash covered by cash on hand, no refinancing forced · both figures from the Jun 30, 2026 balance sheet
Cash runway2.1 yrsthe business is consuming cash; this is how long the cash on hand lasts at that rate
Revenue, latest quarter vs. a year ago+3.0%the freshest read on whether the business is still growing
Current ratio, recent quarters4.9× → 3.0×
Deeper floors
Tangible book value($228M)equity stripped of goodwill & intangibles
Net current asset value($246M)Graham's net-net: current assets less all liabilities
Debt incl. operating leases$8M$1M of it operating leases

From the company's latest filing.

Management, ownership & pay

read the proxy →

From the proxy: how much of the business the people running it own, and how they are paid, beside what the business earned for its owners in the same years.

Fiscal yearPay, as filed“Actually paid”Owner earnings
2023$3.8M$2.7M($122M)
2024$1.8M$4.1M($125M)
2025$2.5M$6.0M($141M)

Both pay figures are the company’s own, from the pay-versus-performance table its proxy statement files. “As filed” is the Summary Compensation Table total: salary, bonus, and equity awards at their value on the day of grant. “Actually paid” is the SEC’s prescribed recalculation, which re-marks those equity awards to what they became as they vested; it can swing far above or below the filed figure in either direction, and negative years occur. Owner earnings are the whole business's, from the record above, for the same fiscal years.

  • Insider ownership5.1%

    The stake all directors and executive officers hold together, per the 2026 proxy: skin in the game, the first thing Munger reads.

  • Stock-based compensation$7M

    The slice of the business handed to employees in shares in fiscal 2025, 8.5% of revenue. Buffett's oldest accounting fight: this is compensation, compensation is an expense, real whether or not the headline earnings admit it. One trap: the cash-flow statement adds SBC back, so the operating cash, and the owner earnings drawn from it, are flattered by exactly this amount; counted as the cost it is, what an owner keeps is lower.

Peers, Pharmaceuticals

The same industry, side by side on owner economics. Each column names the period it is read over, and a median resting on fewer than three years carries that count beside it; the group median at the foot is the line to read each figure against.

CompanyRevenuelatest FY, USDGross marginmedian over the recordOp. marginmedian over the recordROICmedian over the recordOwner earn. marginmedian over the record
SPRYARS Pharmaceuticals Inc.$84M-212.9%-39%-203%
ARCTArcturus Therapeutics Holdings Inc.$82M-93.0%-1913%1y-40%
ADCTADC Therapeutics SA$81M93%-166.9%-175%
ETONEton Pharmaceuticals Inc.$80M60%-6.7%-108%13%
CTMXCytomX Therapeutics Inc.$76M-124.3%-20%1y-81%
BCYCBicycle Therapeutics plc$73M-561.0%-30%2y-236%
ASMBAssembly Biosciences Inc.$72M-369.2%-70%-130%
VRDNViridian Therapeutics Inc.$71M3%1y-476.8%4y-1025%2y-357%4y
Group median60%-189.9%-152%
IV

The price

What a price has to assume.

What the price implies

reverse-DCF

ADC Therapeutics SA is profitable, but owner earnings are negative this year because capital spending currently outruns operating cash, a build-out, so the owner-earnings reverse-DCF has no positive base to grow. We read the price from both ends instead: type a price to see the steady-state profitability it demands, then set the mature margin you would believe and weigh the two against each other. Nothing leaves your browser unless you enter it in your notebook.

$
The assumptions

Revenue, delivered−25%/yr’22→’25

Enter a price to run it.

Owner earnings it must reach
Margin the price demands
Owner-earnings margin today−121%

Two reads of one future. From your price: the owner earnings the company must reach, valued at a mature multiple and discounted back at your rate, expressed as the margin it implies on revenue grown at your rate. From your belief: the mature margin you would credit, set on the dial above. When the margin the price demands runs above the one you would believe, you are paying for a future taken on faith. For a deep cyclical at a trough, normalized through-cycle earnings are the better lens; this mode is for the genuinely unprofitable, and for the profitable business whose capital spending currently outruns its cash.

Cite: Owner Scorecard, "ADC Therapeutics SA (ADCT), the owner's record," https://ownerscorecard.com/c/ADCT, data as of 2026-08-17.

Manual order: ← ADC its page in the Manual ADEA →

Industry order: ← ADAG the Pharmaceuticals chapter AGIO →